Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
A capsule formulation containing 50 mg of isosorbide mononitrate has been developed, 30% of which is in a nonsustained-release form to ensure rapid attainment of initial plasma levels. The remaining 70% is in a sustained-release form that ensures a long-lasting effect and the convenience of once-daily dosing. This formulation of sustained-release isosorbide mononitrate (Elantan LA 50 mg) provides plasma levels greater than 100 ng/ml for 17 hours after oral administration. For the remaining 7 hours, the nitrate plasma level ranges between 50 and 100 ng/ml.
Bonn
R
R
Department of Clinical Pharmacology, Schwarz GmbH, Monheim, Federal Republic of Germany.
D000293:Adolescent; D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy*; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D013607:Tablets
D003692:Delayed-Action Preparations; D013607:Tablets; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate